Stonepine Capital Management LLC Acquires New Stake in Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

Stonepine Capital Management LLC bought a new stake in shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 1,050,000 shares of the biopharmaceutical company's stock, valued at approximately $1,922,000. Inovio Pharmaceuticals comprises 1.6% of Stonepine Capital Management LLC's holdings, making the stock its 19th biggest position. Stonepine Capital Management LLC owned 4.02% of Inovio Pharmaceuticals as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Deep Track Capital LP raised its position in shares of Inovio Pharmaceuticals by 72.9% during the 4th quarter. Deep Track Capital LP now owns 3,119,162 shares of the biopharmaceutical company's stock valued at $5,708,000 after acquiring an additional 1,314,796 shares in the last quarter. AIGH Capital Management LLC bought a new stake in Inovio Pharmaceuticals during the fourth quarter valued at $1,197,000. Bank of America Corp DE raised its holdings in shares of Inovio Pharmaceuticals by 1,035.2% during the fourth quarter. Bank of America Corp DE now owns 640,987 shares of the biopharmaceutical company's stock worth $1,173,000 after purchasing an additional 584,521 shares during the period. Highbridge Capital Management LLC bought a new position in shares of Inovio Pharmaceuticals in the 4th quarter worth about $549,000. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Inovio Pharmaceuticals in the 4th quarter worth about $412,000. Institutional investors and hedge funds own 26.79% of the company's stock.

Analysts Set New Price Targets

INO has been the topic of several research reports. HC Wainwright reiterated a "neutral" rating and set a $3.00 price objective on shares of Inovio Pharmaceuticals in a research note on Wednesday, March 19th. Wall Street Zen cut Inovio Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday, May 12th. Oppenheimer reduced their price objective on Inovio Pharmaceuticals from $15.00 to $13.00 and set an "outperform" rating for the company in a research report on Wednesday, May 14th. Finally, Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $5.00 target price on shares of Inovio Pharmaceuticals in a research report on Wednesday, May 14th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, Inovio Pharmaceuticals presently has a consensus rating of "Hold" and a consensus price target of $9.75.

Inovio Pharmaceuticals Stock Performance

Shares of INO traded down $0.08 during mid-day trading on Friday, reaching $1.95. 197,308 shares of the company's stock traded hands, compared to its average volume of 594,273. The business's 50-day moving average price is $1.80 and its 200-day moving average price is $2.41. The stock has a market capitalization of $71.33 million, a P/E ratio of -0.61 and a beta of 1.40. Inovio Pharmaceuticals, Inc. has a 12 month low of $1.42 and a 12 month high of $12.33.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last announced its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.23. The business had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.01 million. Equities research analysts anticipate that Inovio Pharmaceuticals, Inc. will post -4.23 EPS for the current year.

Inovio Pharmaceuticals Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.